Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: hsg who wrote (348)	1/21/1999 8:23:00 PM
From: Robert Dydo	Read Replies (1) \| Respond to of 572

I think there will be plenty of new developments, which could easily support the level from Levesque's recommendation. Phase III for Life-GI, improvement to Life-Lung making it more commercial, cheaper and in result saleable in larger volumes. Results of cervical, neck and head cancers' feasibility studies. On the top Miravant and Xillix cooperation in combining Xillix technology with Photopoint system. Frankly, I would not be surprised if this stock was eventually trading in double digits as a comfortable price range. The scope of their work continues to be undiscovered by the market and we seem to be little out of luck here with this chock hold type of deal by Olympus, which is rather clinching than broadening the horizons for Xillix, in my opinion, at least based on expectations for such a big partner. Robert